- Home
- CAPR vs LEO Comparison
CAPR vs LEO Comparison
Compare CAPR & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- LEO
- Stock Information
- Founded
- CAPR 2005
- LEO 1987
- Country
- CAPR United States
- LEO United States
- Employees
- CAPR N/A
- LEO N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- LEO Trusts Except Educational Religious and Charitable
- Sector
- CAPR Health Care
- LEO Finance
- Exchange
- CAPR Nasdaq
- LEO Nasdaq
- Market Cap
- CAPR 324.6M
- LEO 362.5M
- IPO Year
- CAPR N/A
- LEO N/A
- Fundamental
- Price
- CAPR $6.08
- LEO $6.24
- Analyst Decision
- CAPR Strong Buy
- LEO
- Analyst Count
- CAPR 8
- LEO 0
- Target Price
- CAPR $24.75
- LEO N/A
- AVG Volume (30 Days)
- CAPR 1.2M
- LEO 200.2K
- Earning Date
- CAPR 11-12-2025
- LEO 01-01-0001
- Dividend Yield
- CAPR N/A
- LEO 4.01%
- EPS Growth
- CAPR N/A
- LEO N/A
- EPS
- CAPR N/A
- LEO 0.04
- Revenue
- CAPR $13,392,150.00
- LEO N/A
- Revenue This Year
- CAPR N/A
- LEO N/A
- Revenue Next Year
- CAPR $7,894.07
- LEO N/A
- P/E Ratio
- CAPR N/A
- LEO $152.00
- Revenue Growth
- CAPR N/A
- LEO N/A
- 52 Week Low
- CAPR $4.59
- LEO $4.98
- 52 Week High
- CAPR $23.40
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- CAPR 40.13
- LEO 77.02
- Support Level
- CAPR $5.97
- LEO $5.83
- Resistance Level
- CAPR $6.57
- LEO $6.20
- Average True Range (ATR)
- CAPR 0.38
- LEO 0.05
- MACD
- CAPR 0.03
- LEO 0.03
- Stochastic Oscillator
- CAPR 36.70
- LEO 94.19
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.